Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia
Abstract
:1. Introduction
2. Schizophrenia
3. Oxidative Stress
4. Mitochondrial ROS Production
5. Association between Oxidative Stress and Schizophrenia
6. Oxidative Damage in Schizophrenia
7. Positive Effects of Nutraceuticals and Antioxidants on Schizophrenia
8. Role of Vitamins in Schizophrenia Treatment
8.1. Roles of Vitamin E and Vitamin C
Sources of Vitamin C and Vitamin E
8.2. Role of Vitamin D
Sources of Vitamin D
8.3. Role of Vitamin B
Sources of Vitamin B
9. Role of Polyunsaturated Fatty Acids in Schizophrenia Treatment
Sources of PUFA
10. Role of Antipsychotics
10.1. Aripiprazole
10.2. Brexpiprazole
10.3. Risperidone
10.4. Lurasidone
10.5. Clozapine
10.6. Chlorpromazine
11. Role of Cognitive Therapies
12. Role of Quality of Life
13. Implications
14. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Ben-Azu, B.; Aderibigbe, A.O.; Ajayi, A.M.; Iwalewa, E.O. Neuroprotective effects of the ethanol stem bark extracts of Terminalia ivorensis in ketamine–induced schizophrenia-like behaviors and oxidative damage in mice. Pharm. Biol. 2016, 54, 2871–2879. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hassan, W.; Silva, C.E.B.; Mohammadzai, I.U.; da Rocha, J.B.T.; Landeira-Fernandez, J. Association of oxidative stress to the genesis of anxiety: Implications for possible therapeutic interventions. Curr. Neuropharmacol. 2014, 12, 120–139. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Taysi, S.; Tascan, A.S.; Ugur, M.G.; Demir, M. Radicals, oxidative/nitrosative stress and preeclampsia. Mini Rev. Med. Chem. 2019, 19, 178–193. [Google Scholar] [CrossRef] [PubMed]
- Nagano, T.; Mizuno, M.; Morita, K.; Nawa, H. Pathological implications of oxidative stress in patients and animal models with schizophrenia: The role of epidermal growth factor receptor signaling. Curr. Top. Behav. Neurosci. 2016, 29, 429–446. [Google Scholar]
- Gonzalez-Liencres, C.; Tas, C.; Brown, E.C.; Erdin, S.; Onur, E.; Cubukcoglu, Z.; Aydemir, O.; Aysen Esen-Danaci, A.; Brüne, M. Oxidative stress in schizophrenia: A case–control study on the effects on social cognition and neurocognition. BMC Psychiatry 2014, 14, 268. [Google Scholar] [CrossRef] [Green Version]
- Bitanihirwe, B.K.Y.; Tsung-Ung, W.; Woo, T.W. Oxidative stress in schizophrenia: An integrated approach. Neurosci. Biobehav. Rev. 2011, 35, 878–893. [Google Scholar] [CrossRef] [Green Version]
- Ciobica, A.; Padurariu, M.; Dobrin, I.; Stefanescu, C.; Dobrin, R. Oxidative stress in schizophrenia—Focusing on the main markers. Psychiatr. Danub. 2011, 23, 237–245. [Google Scholar]
- Liu, Z.; Ren, Z.; Zhang, J.; Chuang, C.C.; Kandaswamy, E.; Zhou, T.; Zuo, L. Role of ROS and nutritional antioxidants in human diseases. Front. Physiol. 2018, 9, 477. [Google Scholar] [CrossRef] [Green Version]
- Dean, O.M.; van den Buuse, M.; Bush, A.I.; Copolov, D.L.; Ng, F.; Dodd, S.; Berk, M. A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. Curr. Med. Chem. 2009, 16, 2965–2976. [Google Scholar] [CrossRef]
- Magalhães, P.V.S.; Dean, O.; Andreazza, A.C.; Berk, M.; Kapczinski, F. Antioxidant treatments for schizophrenia. Cochrane Database Syst. Rev. 2016, 2, CD008919. [Google Scholar] [CrossRef] [Green Version]
- Wadhwa, R.; Gupta, R.; Maurya, P.K. Oxidative stress and accelerated aging in neurodegenerative and neuropsychiatric disorder. Curr. Pharm. Des. 2018, 24, 4711–4725. [Google Scholar] [CrossRef] [PubMed]
- Wood, S.J.; Yücel, M.; Pantelis, C.; Berk, M. Neurobiology of schizophrenia spectrum disorders: The role of oxidative stress. Ann. Acad. Med. 2009, 38, 396–401. [Google Scholar]
- Bahceci, B.; Kokacya, M.H.; Copoglu, U.S.; Bahceci, I.; Sahin, K.; Bagcioglu, E.; Dokuyucu, R. Elevated nucleosome level and oxidative stress in schizophrenia patients. Bratisl Lek Listy 2015, 116, 587–590. [Google Scholar] [CrossRef] [Green Version]
- Jiang, J.; Peng, C.; Sun, L.; Li, J.; Qing, Y.; Hu, X.; Yang, X.; Li, Y.; Xu, C.; Zhang, J.; et al. Leukocyte proteomic profiling in first–episode schizophrenia patients: Does oxidative stress play central roles in the pathophysiology network of schizophrenia? Antioxid. Redox Sign. 2019, 31, 579–588. [Google Scholar] [CrossRef]
- Madireddy, S.; Madireddy, S. Protection from the pathogenesis of neurodegenerative disorders, including alzheimer’s disease, amyotrophic lateral sclerosis, Huntington’s disease, and Parkinson’s diseases, through the mitigation of reactive oxygen species. J. Neurosci. Neurol. Disord. 2019, 3, 148–161. [Google Scholar] [CrossRef] [Green Version]
- Ng, F.; Berk, M.; Dean, O.; Bush, A.I. Oxidative stress in psychiatric disorders: Evidence base and therapeutic implications. Int. J. Neuropsychopharmacol. 2008, 11, 851–876. [Google Scholar] [CrossRef] [Green Version]
- Porokhovnik, L.N.; Passekov, V.P.; Gorbachevskaya, N.L.; Sorokin, A.B.; Veiko, N.N.; Lyapunova, N.A. Active ribosomal genes, translational homeostasis and oxidative stress in the pathogenesis of schizophrenia and autism. Psychiatr. Genet. 2015, 25, 79–87. [Google Scholar] [CrossRef]
- Alhadidi, M.M.; Abdullah, K.L.; Yoong, T.L.; Hadid, L.A.; Danaee, M. A systematic review of randomized controlled trials of psychoeducation interventions for patients diagnosed with schizophrenia. Int. J. Soc. Psychiatry 2020, 66, 542–552. [Google Scholar] [CrossRef]
- Bošković, M.; Grabnar, I.; Terzič, T.; Plesničar, B.K.; Vovk, T. Oxidative stress in schizophrenia patients treated with long–acting haloperidol decanoate. Psychiatry Res. 2013, 210, 761–768. [Google Scholar] [CrossRef]
- Huang, D.; Liu, S. Oxidative stress and schizophrenia. J. Psychiatry Brain Sci. 2017, 2, 4. [Google Scholar]
- Rodríguez, B.; Nani, J.V.; Almeida, P.G.C.; Brietzke, E.; Lee, R.S.; Hayashi, M.A.F. Neuropeptides and oligopeptidases in schizophrenia. Neurosci. Biobehav. Rev. 2020, 108, 679–693. [Google Scholar] [CrossRef] [PubMed]
- Yao, J.K.; Keshavan, M.S. Antioxidants, redox signaling, and pathophysiology in schizophrenia: An integrative view. Antioxid. Redox Sign. 2011, 15, 2011–2035. [Google Scholar] [CrossRef] [PubMed]
- Güneş, M.; Camkurt, M.A.; Bulut, M.; Demir, S.; İbiloğlu, A.O.; Kaya, M.C.; Atl, A.; Kaplan, I.; Sir, A. Evaluation of paraoxonase, arylesterase and malondialdehyde levels in schizophrenia patients taking typical, atypical and combined antipsychotic treatment. Clin. Psychopharma. Neurosci. 2016, 14, 345–350. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Collin, F.; Cheignon, C.; Hureau, C. Oxidative stress as a biomarker for alzheimer’s disease. Biomark. Med. 2018, 12, 201–203. [Google Scholar] [CrossRef]
- Firth, J.; Teasdale, S.B.; Allott, K.; Siskind, D.; Marx, W.; Cotter, J.; Veronese, N.; Schuch, F.; Smith, L.; Solmi, M.; et al. The efficacy and safety of nutrient supplements in the treatment of mental disorders: A meta–review of meta–analyses of randomized controlled trials. World Psychiatry 2019, 18, 308–324. [Google Scholar] [CrossRef] [Green Version]
- Do, K.Q.; Conus, P.; Cuenod, M. Redox dysregulation and oxidative stress in schizophrenia: Nutrigenetics as a challenge in psychiatric disease prevention. In Personalized Nutrition; Simopoulos, A.P., Milner, J.A., Eds.; Karger: Basel, Switzerland, 2010; Volume 101, pp. 131–153. [Google Scholar]
- Jaaro-Peled, H.; Sawa, A. Neurodevelopmental factors in schizophrenia. Psychiatr. Clin. 2020, 43, 263–274. [Google Scholar] [CrossRef]
- Lin, C.-H.; Lane, H.-Y. Early identification and intervention of schizophrenia: Insight from hypotheses of glutamate dysfunction and oxidative stress. Front. Psychiatry 2019, 10, 93. [Google Scholar] [CrossRef]
- Panahi, Y.; Rajaee, S.M.; Johnston, T.P.; Sahebkar, A. Neuroprotective effects of antioxidants in the management of neurodegenerative disorders: A literature review. J. Cell. Biochem. 2019, 120, 2742–2748. [Google Scholar] [CrossRef]
- Do, K.Q.; Cuenod, M.; Hensch, T.K. Targeting Oxidative stress and aberrant critical period plasticity in the developmental trajectory to schizophrenia. Schizophr. Bull. 2015, 41, 835–846. [Google Scholar] [CrossRef]
- Harvey, P.D.; Isner, E.C. Cognition, social cognition, and functional capacity in early—Onset schizophrenia. Child Adolesc. Psychiatr. Clin. 2020, 29, 171–182. [Google Scholar] [CrossRef]
- Zanelli, J.; Mollon, J.; Sandin, S.; Morgan, C.; Dazzan, P.; Pilecka, I.; Marques, T.R.; David, A.; Morgan, K.D.; Fearon, P.; et al. Cognitive change in schizophrenia and other psychoses in the decade following the first episode. Am. J. Psychiatry 2019, 176, 811–819. [Google Scholar] [CrossRef] [PubMed]
- Chowdari, K.V.; Bamne, M.N.; Nimgaonkar, V.L. Genetic association studies of antioxidant pathway genes and schizophrenia. Antioxid. Redox Sign. 2011, 15, 2037–2045. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fischer, E.K.; Drago, A. A molecular pathway analysis stresses the role of inflammation and oxidative stress towards cognition in schizophrenia. J. Neural Transm. 2017, 124, 765–774. [Google Scholar] [CrossRef] [PubMed]
- Zugno, A.I.; Canever, L.; Heylmann, A.S.; Wessler, P.G.; Steckert, A.; Mastella, G.A.; de Oliveira, M.B.; Damázio, L.S.; Pachec, F.D.; Calixto, O.P.; et al. Effect of folic acid on oxidative stress and behavioral changes in the animal model of schizophrenia induced by ketamine. J. Psychiatr. Res. 2016, 81, 23–35. [Google Scholar] [CrossRef] [PubMed]
- Hamazaki, K.; Maekawa, M.; Toyota, T.; Dean, B.; Hamazaki, T.; Yoshikawa, T. Fatty acid composition of the postmortem corpus callosum of patients with schizophrenia, bipolar disorder, or major depressive disorder. Eur. Psychiatry 2017, 39, 51–56. [Google Scholar] [CrossRef] [PubMed]
- van Erp, T.G.; Hibar, D.P.; Rasmussen, J.M.; Glahn, D.C.; Pearlson, G.D.; Andreassen, O.A.; Agartz, I.; Westlye, L.T.; Haukvik, U.K.; Dale, A.M.; et al. Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. Mol. Psychiatry 2016, 21, 547–553. [Google Scholar] [CrossRef] [PubMed]
- Gourion, D.; Gourevitch, R.; Leprovost, J.B.; Olié, H.; Lôo, J.P.; Krebs, M.O. Neurodevelopmental hypothesis in schizophrenia. Encephale 2004, 30, 109–118. [Google Scholar] [CrossRef]
- Guessoum, S.B.; Le Strat, Y.; Dubertret, C.; Mallet, J. A transnosographic approach of negative symptoms pathophysiology in schizophrenia and depressive disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2020, 99, 109862. [Google Scholar] [CrossRef]
- Bulbul, F.; Virit, O.; Alpak, G.; Unal, A.; Bulut, M.; Kaya, M.C.; Altindag, A.; Celik, H.; Savas, H.A. Are oxidative stress markers useful to distinguish schizoaffective disorder from schizophrenia and bipolar disorder? Acta Neuropsychiatr. 2014, 26, 120–124. [Google Scholar] [CrossRef]
- Gainsford, K.; Fitzgibbon, B.; Fitzgerald, P.B.; Hoy, K.E. Transforming treatments for schizophrenia: Virtual reality, brain stimulation and social cognition. Psychiatry Res. 2020, 288, 112974. [Google Scholar] [CrossRef]
- Humpston, C.S.; Broome, M.R. Thinking, believing, and hallucinating self in schizophrenia. Lancet Psychiatry 2020, 7, 638–646. [Google Scholar] [CrossRef]
- Khandaker, G.M.; Dantzer, R. Is there a role for immune–to–brain communication in schizophrenia? Psychopharmacology 2016, 233, 1559–1573. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Khavari, B.; Cairns, M.J. Epigenomic dysregulation in schizophrenia: In search of disease etiology and biomarkers. Cells 2020, 9, 1837. [Google Scholar] [CrossRef] [PubMed]
- Smeland, O.B.; Frei, O.; Dale, A.M.; Andreassen, O.A. The polygenic architecture of schizophrenia—Rethinking pathogenesis and nosology. Nat. Rev. Neurol. 2020, 16, 366–379. [Google Scholar] [CrossRef] [PubMed]
- Correll, C.U.; Schooler, N.R. Negative symptoms in schizophrenia: A review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr. Dis. Treat. 2020, 16, 519–534. [Google Scholar] [CrossRef] [Green Version]
- Krug, A.; Stein, F.; Kircher, T. Cognitive disorders in schizophrenia. Nervenarzt 2020, 91, 2–9. [Google Scholar] [CrossRef]
- Pu, S.; Nakagome, K.; Itakura, M.; Iwata, M.; Nagata, I.; Kaneko, K. The association between cognitive deficits and prefrontal hemodynamic responses during performance of working memory task in patients with schizophrenia. Schizophr. Res. 2016, 172, 114–122. [Google Scholar] [CrossRef]
- Wright, S.; Kochunov, P.; Chiappelli, J.; McMahon, R.; Muellerklein, F.; Wijtenburg, S.A.; White, M.G.; Rowland, L.M.; Hong, E. Accelerated white matter aging in schizophrenia: Role of white matter blood perfusion. Neurobiol. Aging 2014, 35, 2411–2418. [Google Scholar] [CrossRef] [Green Version]
- Kim, G.H.; Kim, J.E.; Rhie, S.J.; Yoon, S. The role of oxidative stress in neurodegenerative diseases. Exp. Neurobiol. 2015, 24, 325–340. [Google Scholar] [CrossRef]
- Salim, S. Oxidative stress and the central nervous system. J. Pharmacol. Exp. Ther. 2017, 360, 201–205. [Google Scholar] [CrossRef]
- Sbodio, J.I.; Snyder, S.H.; Paul, B.D. Redox mechanisms in neurodegeneration: From disease outcomes to therapeutic opportunities. Antioxid. Redox Sign. 2019, 30, 1450–1499. [Google Scholar] [CrossRef] [PubMed]
- Newsholme, P.; Cruzat, V.F.; Keane, K.N.; Carlessi, R.; de Bittencourt, P.I.H. Molecular mechanisms of ROS production and oxidative stress in diabetes. Biochem. J. 2016, 473, 4527–4550. [Google Scholar] [CrossRef] [PubMed]
- Okusaga, O.O. Accelerated aging in schizophrenia patients: The potential role of oxidative stress. Aging Dis. 2014, 5, 256–262. [Google Scholar] [PubMed]
- Pizzino, G.; Irrera, N.; Cucinotta, M.; Pallio, G.; Mannino, F.; Arcoraci, V.; Squadrito, F.; Altavilla, D.; Bitto, A. Oxidative stress: Harms and benefits for human health. Oxid. Med. Cell. Longev. 2017, 2017, 8416763. [Google Scholar] [CrossRef] [PubMed]
- Lu, J.; Wang, Z.; Cao, J.; Chen, Y.; Dong, Y. A novel and compact review on the role of oxidative stress in female reproduction. Reprod. Biol. Endocrinol. 2018, 16, 80. [Google Scholar] [CrossRef] [PubMed]
- Nita, M.; Grzybowski, A. The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults. Oxid. Med. Cell. Longev. 2016, 2016, 3164734. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Collin, F. Chemical basis of reactive oxygen species reactivity and involvement in neurodegenerative diseases. Int. J. Mol. Sci. 2019, 20, 2407. [Google Scholar] [CrossRef] [Green Version]
- Kawamura, T.; Muraoka, I. Exercise–induced oxidative stress and the effects of antioxidant intake from a physiological viewpoint. Antioxidants 2018, 7, 119. [Google Scholar] [CrossRef] [Green Version]
- Rahal, A.; Kumar, A.; Singh, V.; Yadav, B.; Tiwari, R.; Chakraborty, S.; Chakraborty, S.; Dhama, K. Oxidative stress, prooxidants, and antioxidants: The interplay. BioMed Res. Int. 2014, 2014, 761264. [Google Scholar] [CrossRef] [Green Version]
- Singh, A.; Kukreti, R.; Saso, L.; Kukreti, S. Oxidative stress: A key modulator in neurodegenerative diseases. Molecules 2019, 24, 1583. [Google Scholar] [CrossRef] [Green Version]
- Wang, Y.; Branicky, R.; Noë, A.; Hekimi, S. Superoxide dismutases: Dual roles in controlling ROS damage and regulating ROS signaling. J. Cell. Biol. 2018, 217, 1915–1928. [Google Scholar] [CrossRef] [PubMed]
- Zorov, D.B.; Juhaszova, M.; Sollott, S.J. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol. Rev. 2014, 94, 909–950. [Google Scholar] [CrossRef] [Green Version]
- Bolisetty, S.; Jaimes, E.A. Mitochondria and reactive oxygen species: Physiology and pathophysiology. Int. J. Mol. Sci. 2013, 14, 6306–6344. [Google Scholar] [CrossRef] [PubMed]
- Das, K.; Roychoudhury, A. Reactive oxygen species (ROS) and response of antioxidants as ROS-scavengers during environmental stress in plants. Front. Environ. Sci. 2014, 2, 53. [Google Scholar] [CrossRef] [Green Version]
- Bai, Z.; Li, X.; Chen, G.; Du, Y.; Wei, Z.; Chen, X.; Zheng, G.; Deng, W.; Cheng, Y. Serum oxidative stress marker levels in unmedicated and medicated patients with schizophrenia. J. Mol. Neurosci. 2018, 66, 428–436. [Google Scholar] [CrossRef] [PubMed]
- Chittiprol, S.; Venkatasubramanian, G.; Neelakantachar, N.; Babu, S.V.; Reddy, N.A.; Shetty, K.T.; Gangadhar, B.N. Oxidative stress and neopterin abnormalities in schizophrenia: A longitudinal study. J. Psychiatr. Res. 2010, 44, 310–313. [Google Scholar] [CrossRef] [PubMed]
- Sarandol, A.; Kirli, S.; Akkaya, C.; Altin, A.; Demirci, M.; Sarandol, E. Oxidative–antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: Effects of short term antipsychotic treatment. Prog. Neuro–Psychopharmacol. Biol. Psychiatry 2007, 31, 1164–1169. [Google Scholar] [CrossRef] [PubMed]
- Alvarez-Arellano, L.; González-García, N.; Salazar-García, M.; Corona, J.C. Antioxidants as a potential target against inflammation and oxidative stress in attention-deficit/hyperactivity disorder. Antioxidants 2020, 9, 176. [Google Scholar] [CrossRef] [Green Version]
- Leza, J.C.; García–Bueno, B.; Bioque, M.; Arango, C.; Parellada, M.; Do, K.; O’Donnell, P.; Bernardo, M. Inflammation in schizophrenia: A question of balance. Neurosci. Biobehav. Rev. 2015, 55, 612–626. [Google Scholar] [CrossRef]
- Muller, N. Inflammation in schizophrenia: Pathogenetic aspects and therapeutic considerations. Schizophr. Bull. 2018, 44, 973–982. [Google Scholar] [CrossRef] [Green Version]
- Mehta, V.; Desai, N.; Perwez, A.; Nemade, D.; Dawoodi, S.; Zaman, S.B. ACE alzheimer’s: The role of vitamin A, C and E (ACE) in oxidative stress induced alzheimer’s disease. J. Med. Res. Innov. 2018, 2. [Google Scholar] [CrossRef]
- Sharma, P.; Jha, A.B.; Dubey, R.S.; Pessarakli, M. Reactive oxygen species, oxidative damage, and antioxidative defense mechanism in plants under stressful conditions. J. Bot. 2012, 2012, 217037. [Google Scholar] [CrossRef] [Green Version]
- He, Q.; You, Y.; Yu, L.; Yao, L.; Lu, H.; Zhou, X.; Wu, S.; Chen, L.; Chen, Y.; Zhao, X. Uric acid levels in subjects with schizophrenia: A systematic review and meta-analysis. Psychiatry Res. 2020, 292, 113305. [Google Scholar] [CrossRef]
- Dietrich-Muszalska, A.; Kolińska-Łukaszuk, J. Comparative effects of aripiprazole and selected antipsychotic drugs on lipid peroxidation in plasma. Psychiatry Clin. Neurosci. 2018, 72, 329–336. [Google Scholar] [CrossRef] [Green Version]
- Forni, C.; Facchiano, F.; Bartoli, M.; Pieretti, S.; Facchiano, A.; D’Arcangelo, D.; Norelli, S.; Valle, G.; Nisini, R.; Beninati, S.; et al. Beneficial role of phytochemicals on oxidative stress and age-related diseases. BioMed Res. Int. 2019, 2019, 8748253. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jha, S.K.; Jha, N.K.; Kumar, D.; Ambasta, R.K.; Kumar, P. Linking mitochondrial dysfunction, metabolic syndrome and stress signaling in neurodegeneration. Mol. Basis Dis. 2017, 1863, 1132–1146. [Google Scholar] [CrossRef] [PubMed]
- Chandel, N.S. Mitochondria as signaling organelles. BMC Biol. 2014, 12, 34. [Google Scholar] [CrossRef]
- Wang, X.; Wang, W.; Lia, L.; Perry, G.; Lee, H.; Zhu, X. Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease. Biochim. Biophys. Acta 2014, 1842, 1240–1247. [Google Scholar] [CrossRef] [Green Version]
- Idelchik, M.P.S.; Begley, U.; Begley, T.J.; Melendez, J.A. Mitochondrial ROS control of cancer. Semin. Cancer Biol. 2017, 47, 57–66. [Google Scholar] [CrossRef]
- Angelova, P.R.; Abramov, A.Y. Role of mitochondrial ROS in the brain: From physiology to neurodegeneration. FEBS Lett. 2018, 592, 692–702. [Google Scholar] [CrossRef]
- Akbar, M.; Essa, M.M.; Daradkeh, G.; Abdelmegeeda, M.A.; Choia, Y.; Mahmoodd, L.; Song, B. Mitochondrial dysfunction and cell death in neurodegenerative diseases through nitroxidative stress. Brain Res. 2016, 1637, 34–55. [Google Scholar] [CrossRef] [PubMed]
- Dunn, J.D.; Alvarez, L.A.; Zhang, X.; Soldati, T. Reactive oxygen species and mitochondria: A nexus of cellular homeostasis. Redox Biol. 2015, 6, 472–485. [Google Scholar] [CrossRef]
- Roberts, R.C. Postmortem studies on mitochondria in schizophrenia. Schizophr. Res. 2017, 187, 17–25. [Google Scholar] [CrossRef]
- An, H.; Du, X.; Huang, X.; Qi, L.; Jia, Q.; Yin, G.; Xiao, C.; Huang, X.; Ning, Y.; Cassidy, R.M.; et al. Obesity, altered oxidative stress, and clinical correlates in chronic schizophrenia patients. Transl. Psychiatry 2018, 8, 258. [Google Scholar] [CrossRef]
- Boll, K.M.; Noto, C.; Bonifácio, K.L.; Bortolasci, C.C.; Gadelha, A.; Bressan, R.A.; Barbosa, D.S.; Maes, M.; Moreira, E.G. Oxidative and nitrosative stress biomarkers in chronic schizophrenia. Psychiatry Res. 2017, 253, 43–48. [Google Scholar] [CrossRef]
- Fraguas, D.; Diaz-Caneja, C.M.; Ayora, M.; Hernandez-Alvarez, F.; Rodriguez-Quiroga, A.; Recio, S.; Leza, J.C.; Arango, C. Oxidative stress and inflammation in first–episode psychosis: A systematic review and meta-analysis. Schizophr. Bull. 2019, 45, 742–751. [Google Scholar] [CrossRef]
- Jordan, W.; Dobrowolny, H.; Bahn, S.; Bernstein, H.G.; Brigadski, T.; Frodl, T.; Isermann, B.; Lessmann, V.; Pilz, J.; Rodenbeck, A.; et al. Oxidative stress in drug–naïve first episode patients with schizophrenia and major depression: Effects of disease acuity and potential confounders. Eur. Arch. Psychiatry Clin. Neurosci. 2018, 268, 129–143. [Google Scholar] [CrossRef] [PubMed]
- Magaji, M.G.; Iniaghe, L.O.; Abolarin, M.; Abdullahi, O.I.; Magaji, R.A. Neurobehavioural evaluation of resveratrol in murine models of anxiety and schizophrenia. Metab. Brain Dis. 2017, 32, 437–442. [Google Scholar] [CrossRef]
- Steullet, P.; Cabungcal, J.; Coyle, J.; Didriksen, M.; Gill, K.; Grace, A.A.; Hensch, T.K.; LaMantia, A.-S.; Lindemann, L.; Maynard, T.M.; et al. Oxidative stress–driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia. Mol. Psychiatry 2017, 22, 936–943. [Google Scholar] [CrossRef] [PubMed]
- Wu, J.Q.; Kosten, T.R.; Zhang, X.Y. Free radicals, antioxidant defense systems, and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 46, 200–206. [Google Scholar] [CrossRef]
- Mueller, T.M.; Meador-Woodruff, J.H. Post-translational protein modifications in schizophrenia. NPJ Schizophr. 2020, 6, 5. [Google Scholar] [CrossRef] [PubMed]
- Conn, K.A.; Burne, T.H.J.; Kesby, J.P. Subcortical dopamine and cognition in schizophrenia: Looking beyond psychosis in preclinical models. Front. Neurosci. 2020, 14, 542. [Google Scholar] [CrossRef] [PubMed]
- González-Blanco, L.; García-Portilla, M.P.; García-Álvarez, L.; de la Fuente-Tomás, L.; García, C.I.; Sáiz, P.A. Oxidative stress biomarkers and clinical dimensions in first 10 years of schizophrenia. Rev. Psiquiatr. Salud Ment. 2018, 11, 130–140. [Google Scholar] [CrossRef] [PubMed]
- Miljević, Č.D.; Nikolić-Kokić, A.; Blagojević, D.; Milovanović, M.; Munjiza, A.; Jukić, M.M.; Pešić, V.; Lečić-Toševski, D.; Spasić, M.B. Association between neurological soft signs and antioxidant enzyme activity in schizophrenic patients. Psychiatry Res. 2018, 269, 746–752. [Google Scholar] [CrossRef]
- Morera-Fumero, A.L.; Diaz-Mesa, E.; Abreu-Gonzalez, P.; Fernandez-Lopez, L.; Cejas-Mendez, M.D. Low levels of serum total antioxidant capacity and presence at admission and absence at discharge of a day/night change as a marker of acute paranoid schizophrenia relapse. Psychiatry Res. 2017, 249, 200–205. [Google Scholar] [CrossRef]
- Nucifora, L.G.; Tanaka, T.; Hayes, L.N.; Kim, M.; Lee, B.J.; Matsuda, T.; Nucifora, F.C.; Sedlak, T.; Mojtabai, R.; Eaton, W.; et al. Reduction of plasma glutathione in psychosis associated with schizophrenia and bipolar disorder in translational psychiatry. Transl. Psychiatry 2017, 7, e1215. [Google Scholar] [CrossRef] [Green Version]
- Tunçel, Ö.K.; Sarısoy, G.; Bilgici, B.; Pazvantoglu, O.; Çetin, E.; Ünverdi, E.; Avcı, B.; Böke, O. Oxidative stress in bipolar and schizophrenia patients. Psychiatry Res. 2015, 228, 688–694. [Google Scholar] [CrossRef]
- Zhang, Y.; Catts, V.S. Shannon Weickert, C. Lower antioxidant capacity in the prefrontal cortex of individuals with schizophrenia. Aust. N. Z. J. Psychiatry 2018, 52, 690–698. [Google Scholar] [CrossRef]
- Zhang, X.Y.; Chen, D.-C.; Tan, Y.-L.; Tan, S.-P.; Wang, Z.-R.; Yang, F.-D.; Okusaga, O.O.; Zunta-Soares, G.B.; Soares, J.C. The interplay between BDNF and oxidative stress in chronic schizophrenia. Psychoneuroendocrinology 2015, 51, 201–208. [Google Scholar] [CrossRef]
- Devanarayanan, S.; Nandeesha, H.; Kattimani, S.; Sarkar, S. Relationship between matrix metalloproteinase–9 and oxidative stress in drug–free male schizophrenia: A case control study. Clin. Chem. Lab. Med. 2016, 54, 447–452. [Google Scholar] [CrossRef]
- Avval, F.Z.; Mahmoudi, N.; Tirkani, A.N.; Jarahi, L.; Alamdari, D.H.; Sadjadi, S.A. Determining pro–oxidant antioxidant balance (PAB) and total antioxidant capacity (TAC) in patients with schizophrenia. Iran. J. Psychiatry 2018, 13, 223–227. [Google Scholar]
- Zhang, M.; Zhao, Z.M.; He, L.; Wan, C. A meta–analysis of oxidative stress markers in schizophrenia. Sci. China Life Sci. 2010, 53, 112–124. [Google Scholar] [CrossRef]
- Martins-de-Souza, D.; Harris, L.W.; Guest, P.C.; Bahn, S. The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. Antioxid. Redox Sign. 2011, 15, 2067–2079. [Google Scholar] [CrossRef] [PubMed]
- Vidal, P.M.; Pacheco, R. The cross-talk between the dopaminergic and the immune system involved in schizophrenia. Front. Pharmacol. 2020, 11, 394. [Google Scholar] [CrossRef] [PubMed]
- Vidovic, B.; Milovanovi, S.; Dordevic, B.; Kotur-Stevuljevi, J.; Stefanovic, A.; Ivaniševic, J.; Miljković, M.; Spasić, S.; Stojanović, D.; Pantović, M. Effect of alpha-lipoic acid supplementation on oxidative stress markers and antioxidative defense in patients with schizophrenia. Psychiat. Danub. 2014, 26, 205–213. [Google Scholar]
- Kim, Y.; Na, K. Neuroprotection in schizophrenia and its therapeutic implications. Psychiatry Investig. 2017, 14, 383–391. [Google Scholar] [CrossRef] [Green Version]
- Rajasekaran, A.; Venkatasubramanian, G.; Berk, M.; Debnath, M. Mitochondrial dysfunction in schizophrenia: Pathways, mechanisms and implications. Neurosci. Biobehav. Rev. 2015, 48, 10–21. [Google Scholar] [CrossRef]
- Marazziti, D.; Baroni, S.; Picchetti, M.; Landi, P.; Silvestri, S.; Vatteroni, E.; Dell’Osso, M.C. Psychiatric disorders and mitochondrial dysfunctions. Eur. Rev. Med. Pharmacol. Sci. 2012, 16, 270–275. [Google Scholar]
- Johri, A.; Beal, M.F. Antioxidants in Huntington’s disease. Biochim. Biophys. Acta 2012, 1822, 664–674. [Google Scholar] [CrossRef] [Green Version]
- Conus, P.; Seidman, L.J.; Fournier, M.; Xin, L.; Cleusix, M.; Baumann, P.S.; Ferrari, C.; Cousins, A.; Alameda, L.; Gholam-Rezaee, M.; et al. N-acetylcysteine in a double-blind randomized placebo-controlled trial: Toward biomarker-guided treatment in early psychosis. Schizophr. Bull. 2018, 44, 317–327. [Google Scholar] [CrossRef] [Green Version]
- Perkins, D.O.; Jeffries, C.D.; Addington, J.; Bearden, C.E.; Cadenhead, K.S.; Cannon, T.D.; Cornblatt, B.A.; Mathalon, D.H.; McGlashan, T.H.; Seidman, L.J.; et al. Toward a psychosis risk blood diagnostic for persons experiencing high–risk symptoms: Preliminary results from the NAPLS project. Schizophr. Bull. 2015, 41, 419–428. [Google Scholar] [CrossRef] [PubMed]
- Wu, J.Q.; Chen, D.C.; Tan, Y.L.; Tan, S.; Wang, Z.; Yang, F.; Soares, J.C.; Zhang, X.Y. Association of altered CuZn superoxide dismutase and cognitive impairment in schizophrenia patients with tardive dyskinesia. J. Psychiatr. Res. 2014, 58, 167–174. [Google Scholar] [CrossRef] [PubMed]
- Flatow, J.; Buckley, P.; Miller, B.J. Meta-analysis of oxidative stress in schizophrenia. Biol. Psychiatry 2013, 74, 400–409. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dietrich-Muszalska, A.; Olas, B.; Rabe-Jablonska, J. Oxidative stress in blood platelets from schizophrenic patients. Platelets 2005, 16, 386–391. [Google Scholar] [CrossRef] [PubMed]
- Raffa, M.; Atig, F.; Mhalla, A.; Kerkeni, A.; Mechri, A. Decreased glutathione levels and impaired antioxidant enzyme activities in drug–naïve first–episode schizophrenic patients. BMC Psychiatry 2011, 11, 124. [Google Scholar] [CrossRef] [Green Version]
- Raffa, M.; Barhoumi, S.; Atig, F.; Fendri, C.; Kerkeni, A.; Mechri, A. Reduced antioxidant defense systems in schizophrenia and bipolar I disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 39, 371–375. [Google Scholar] [CrossRef]
- Yao, J.K.; Reddy, R. Oxidative Stress in Schizophrenia: Pathogenetic and Therapeutic Implications. Antioxid. Redox Sign. 2011, 15, 1999–2002. [Google Scholar] [CrossRef] [Green Version]
- Dadheech, G.; Mishra, S.; Gautam, S.; Sharma, P. Evaluation of antioxidant deficit in schizophrenia. Indian J. Psychiatry 2008, 50, 16–20. [Google Scholar]
- Dadheech, G.; Sharma, P.; Gautam, S. Oxidative stress–induced response of some endogenous antioxidants in schizophrenia. Indian J. Clin. Biochem. 2012, 27, 278–283. [Google Scholar] [CrossRef] [Green Version]
- Perkins, D.O.; Jeffries, C.D.; Do, K.Q. Potential roles of redox dysregulation in the development of schizophrenia. Biol. Psychiatry 2020, 88, 326–336. [Google Scholar] [CrossRef]
- Federico, A.; Cardaioli, E.; da Pozzo, P.; Formichi, P.; Gallus, G.N.; Radi, E. Mitochondria, oxidative stress and neurodegeneration. J. Neurol. Sci. 2012, 322, 254–262. [Google Scholar] [CrossRef] [PubMed]
- Song, P.; Zou, M.H. Roles of reactive oxygen species in physiology and pathology. In Atherosclerosis: Risks, Mechanisms, and Therapies; Wang, H., Patterson, C., Eds.; John Wiley & Sons Inc: Hoboken, NJ, USA, 2015; pp. 379–392. [Google Scholar] [CrossRef]
- Boskovic, M.; Vovk, T.; Plesnicar, B.K.; Grabnar, I. Oxidative stress in schizophrenia. Curr. Neuropharmacol. 2011, 9, 301–312. [Google Scholar] [PubMed] [Green Version]
- Upthegrove, R.; Khandaker, G.M. Cytokines, oxidative stress and cellular markers of inflammation in schizophrenia. Curr. Top. Behav. Neurosci. 2020, 44, 49–66. [Google Scholar] [PubMed]
- Barron, H.; Hafizi, S.; Andreazza, A.C.; Mizrahi, R. Neuroinflammation and oxidative stress in psychosis and psychosis risk. Int. J. Mol. Sci. 2017, 18, 651. [Google Scholar] [CrossRef] [Green Version]
- Carocci, A.; Catalano, A.; Sinicropi, M.S.; Genchi, G. Oxidative stress and neurodegeneration: The involvement of iron. BioMetals 2018, 31, 715–735. [Google Scholar] [CrossRef]
- Tan, S.H.; Karri, V.; Tay, N.W.R.; Chang, K.H.; Ah, H.Y.; Ng, P.Q.; Ho, H.S.; Keh, H.W.; Candasamy, M. Emerging pathways to neurodegeneration: Dissecting the critical molecular mechanisms in alzheimer’s disease, Parkinson’s disease. Biomed. Pharmacother. 2019, 111, 765–777. [Google Scholar] [CrossRef]
- Yao, J.K.; Leonard, S.; Reddy, R.D. Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. Schizophr. Bull. 2004, 30, 923–934. [Google Scholar] [CrossRef] [Green Version]
- Dadheech, G.; Mishra, S.; Gautam, S.; Sharma, P. Oxidative stress, α-tocopherol, ascorbic acid and reduced glutathione status in schizophrenics. Indian J. Clin. Biochem. 2006, 21, 34–38. [Google Scholar] [CrossRef] [Green Version]
- Maas, D.A.; Vallès, A.; Martens, G.J.M. Oxidative stress, prefrontal cortex hypomyelination and cognitive symptoms in schizophrenia. Transl. Psychiatry 2017, 7, e1171. [Google Scholar] [CrossRef] [Green Version]
- Mhillaj, E.; Morgese, M.G.; Trabace, L. Early life and oxidative stress in psychiatric disorders: What can we learn from animal models? Curr. Pharm. Des. 2015, 21, 396–403. [Google Scholar] [CrossRef]
- Young, J.; McKinney, S.B.; Ross, B.M.; Wahle, K.W.; Boyle, S.P. Biomarkers of oxidative stress in schizophrenic and control subjects. Prostaglandins Leukot. Essent. Fatty Acids 2007, 76, 73–85. [Google Scholar] [CrossRef] [PubMed]
- Sertan Copoglu, U.; Virit, O.; Hanifi Kokacya, M.; Orkmez, M.; Bulbul, F.; Binnur Erbagci, A.; Semiz, M.; Alpak, G.; Unal, A.; Ari, M.; et al. Increased oxidative stress and oxidative DNA damage in non–remission schizophrenia patients. Psychiatry Res. 2015, 229, 200–205. [Google Scholar] [CrossRef] [PubMed]
- Kilic, O.H.T.; Aksoy, I.; Elboga, G.C.; Bulbul, F. Oxidative parameters, oxidative DNA damage, and urotensin–II in schizoaffective disorder patients. Psychiatry Clin. Psychopharmacol. 2019, 29, 151–157. [Google Scholar] [CrossRef] [Green Version]
- Li, H.C.; Chen, Q.Z.; Ma, Y.; Zhou, J. Imbalanced free radicals and antioxidant defense systems in schizophrenia: A comparative study. J. Zhejiang Univ. Sci. B 2006, 7, 981–986. [Google Scholar]
- Virit, O.; Altindag, A.; Yumru, M.; Dalkilic, A.; Savas, H.A.; Selek, S.; Erel, O.; Herken, H. A defect in the antioxidant defense system in schizophrenia. Neuropsychobiology 2009, 60, 87–93. [Google Scholar] [CrossRef]
- Bjorklund, G.; Chirumbolo, S. Role of oxidative stress and antioxidants in daily nutrition and human health. Nutrition 2017, 33, 311–321. [Google Scholar] [CrossRef]
- Firth, J.; Stubbs, B.; Sarris, J.; Rosenbaum, S.; Teasdale, S.; Berk, M.; Yung, A.R. The effects of vitamin and mineral supplementation on symptoms of schizophrenia: A systematic review and meta-analysis. Psychol. Med. 2017, 47, 1515–1527. [Google Scholar] [CrossRef] [Green Version]
- Visioli, F.; Burgos-Ramos, E. Selected micronutrients in cognitive decline prevention and therapy. Mol. Neurobiol. 2016, 53, 4083–4093. [Google Scholar] [CrossRef]
- Tsai, M.C.; Liou, C.W.; Lin, T.K.; Lin, I.M.; Huang, T.L. Changes in oxidative stress markers in patients with schizophrenia: The effect of antipsychotic drugs. Psychiatry Res. 2013, 209, 284–290. [Google Scholar] [CrossRef]
- D’Souza, B.; D’Souza, V. Oxidative injury and antioxidant vitamins E and C in schizophrenia. Indian J. Clin. Biochem. 2003, 18, 87–90. [Google Scholar] [CrossRef] [Green Version]
- Arvindakshan, M.; Ghate, M.; Ranjekar, P.K.; Evans, D.R.; Mahadik, S.P. Supplementation with a combination of omega 3 fatty acids and antioxidants (vitamin E and C) improves the outcome of schizophrenia. Schizophr. Res. 2003, 62, 195–204. [Google Scholar] [CrossRef]
- Albayrak, Y.; Ünsal, C.; Beyazyüz, M.; Ünal, A.; Kuloğlu, M. Reduced total antioxidant level and increased oxidative stress in patients with deficit schizophrenia: A preliminary study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 45, 144–149. [Google Scholar] [CrossRef] [PubMed]
- Mitra, S.; Natarajan, R.; Ziedonis, D.; Fan, X. Antioxidant and anti–inflammatory nutrient status, supplementation, and mechanisms in patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2017, 78, 1–11. [Google Scholar] [CrossRef] [PubMed]
- Solberg, D.K.; Refsum, H.; Andreassen, O.A.; Bentsen, H. A five-year follow-up study of antioxidants, oxidative stress and polyunsaturated fatty acids in schizophrenia. Acta Neuropsychiatr. 2019, 31, 202–212. [Google Scholar] [CrossRef]
- Fond, G.; Lançon, C.; Korchia, T.; Auquier, P.; Boyer, L. The role of inflammation in the treatment of schizophrenia. Front. Psychiatry 2020, 11, 160. [Google Scholar] [CrossRef] [Green Version]
- Reyazuddin, M.; Azmi, S.A.; Islam, N.; Rizvi, A. Oxidative stress and level of antioxidant enzymes in drug-naive schizophrenics. Indian J. Psychiatry 2014, 56, 344–349. [Google Scholar]
- Kaplan, B.J.; Rucklidge, J.J.; Romijn, A.; McLeod, K. The emerging field of nutritional mental health inflammation, the microbiome, oxidative stress, and mitochondrial function. Clin. Psychol. Sci. 2015, 3, 964–980. [Google Scholar] [CrossRef] [Green Version]
- Rucklidge, J.J.; Kaplan, B.J. Broad-spectrum micronutrient formulas for the treatment of psychiatric symptoms: A systematic review. Expert Rev. Neurother. 2013, 13, 49–73. [Google Scholar] [CrossRef]
- Basambombo, L.L.; Carmichael, P.H.; Cote, S.; Laurin, D. Use of vitamin E and C supplements for the prevention of cognitive decline. Ann. Pharmacother. 2017, 51, 118–124. [Google Scholar] [CrossRef]
- Dipasquale, S.; Pariante, C.M.; Dazzan, P.; Aguglia, E.; McGuire, P.; Mondelli, V. The dietary pattern of patients with schizophrenia: A systematic review. J. Psychiatr. Res. 2013, 47, 197–207. [Google Scholar] [CrossRef] [Green Version]
- Heald, A.; Sein, K.; Anderson, S.; Pendlebury, J.; Guy, M.; Narayan, V.; Gibson, M.; Haddad, P.; Livingston, M. Diet, exercise and the metabolic syndrome in schizophrenia: A cross–sectional study. Schizophr. Res. 2015, 169, 494–495. [Google Scholar] [CrossRef] [PubMed]
- Sarris, J.; Murphy, J.; Mischoulon, D.; Papakostas, G.I.; Fava, M.; Berk, M.; Ng, C.H. Adjunctive nutraceuticals for depression: A systematic review and meta–analyses. Am. J. Psychiatry 2016, 173, 575–587. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ghodake, S.R.; Suryakar, A.N.; Padalkar, R.K. The possible role of oxidants and antioxidant imbalance in pathophysiology of schizophrenia. Int. J. Med. Res. Health Sci. 2012, 2, 19–35. [Google Scholar]
- Reddy, R.; Reddy, R. Antioxidant therapeutics for schizophrenia. Antioxid. Redox Sign. 2011, 15, 2047–2055. [Google Scholar] [CrossRef]
- Taghizadeh, M.; Tamtaji, O.R.; Dadgostar, E.; Kakhaki, R.D.; Bahmani, F.; Abolhassani, J.; Aarabi, M.H.; Kouchaki, E.; Memarzadeh, M.R.; Asemi, Z. The effects of omega-3 fatty acids and vitamin E co-supplementation on clinical and metabolic status in patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. Neurochem. Int. 2017, 108, 183–189. [Google Scholar] [CrossRef]
- Trotta, E.; Bortolotti, S.; Fugazzotto, G.; Gellera, C.; Montagnese, S.; Amodio, P. Familial vitamin E deficiency: Multiorgan complications support the adverse role of oxidative stress. Nutrition 2019, 63–64, 57–60. [Google Scholar] [CrossRef]
- Ulatowski, L.M.; Manor, D. Vitamin E and neurodegeneration. Neurobiol. Dis. 2015, 84, 78–83. [Google Scholar] [CrossRef]
- Koga, M.; Serritella, A.V.; Sawa, A.; Sedlak, T.W. Implications for reactive oxygen species in schizophrenia pathogenesis. Schizophr. Res. 2016, 176, 52–71. [Google Scholar] [CrossRef]
- Arroll, M.A.; Wilder, L.; Neil, J. Nutritional interventions for the adjunctive treatment of schizophrenia: A brief review. Nutr. J. 2014, 13, 1–9. [Google Scholar] [CrossRef] [Green Version]
- Soares-Weiser, K.; Maayan, N.; McGrath, J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst. Rev. 2011, 2, CD000209. [Google Scholar] [CrossRef] [Green Version]
- Bošković, M.; Vovk, T.; Koprivšek, J.; Plesnicar, B.K.; Grabnar, I. Vitamin E and essential polyunsaturated fatty acids supplementation in schizophrenia patients treated with haloperidol. Nutr. Neurosci. 2016, 19. [Google Scholar] [CrossRef] [PubMed]
- Eckert, G.P. The role of vitamin E in aging and alzheimer’s disease. In Vitamin E in Human Health; Weber, P., Birringer, M., Blumberg, J., Eggersdorfer, M., Frank, J., Eds.; Nutrition and Health. Humana Press: Cham, Switzerland, 2019; pp. 325–344. [Google Scholar]
- Grimm, M.O.W.; Mett, J.; Hartmann, T. The impact of vitamin E and other fat-soluble vitamins on alzheimer’s disease. Int. J. Mol. Sci. 2016, 17, 1785. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schirinzi, T.; Martella, G.; Imbriani, P.; Lazzaro, G.D.; Franco, D.; Colona, V.L.; Alwardat, M.; Salimei, P.S.; Mercuri, N.B.; Pierantozzi, M.; et al. Dietary vitamin E as a protective factor for Parkinson’s disease: Clinical and experimental evidence. Front. Neurol. 2019, 10, 148. [Google Scholar] [CrossRef] [Green Version]
- Kocot, J.; Luchowska-Kocot, D.; Kiełczykowska, M.; Musik, I.; Kurzepa, J. Does vitamin C influence neurodegenerative diseases and psychiatric disorders? Nutrients 2017, 9, 659. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Han, Q.-Q.; Shen, T.-T.; Wang, F.; Wu, P.-F.; Chen, J.-G. Preventive and therapeutic potential of vitamin C in mental disorders. Curr. Med. Sci. 2018, 38, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Harrison, F.E. A critical review of vitamin C for the prevention of age-related cognitive decline and alzheimer’s disease. J. Alzheimer’s Dis. 2012, 29, 711–726. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Popovic, L.M.; Mitic, N.R.; Miric, D.; Bisevac, B.; Miric, M.; Popovic, B. Influence of vitamin C supplementation on oxidative stress and neutrophil inflammatory response in acute and regular exercise. Oxid. Med. Cell. Longev. 2015, 2015, 295497. [Google Scholar] [CrossRef]
- Dasgupta, J.; Dasgupta, S.; Rajni; Singh, R.K. Role of free radicals and antioxidants in schizophernia. Int. J. Pharm. Chem. Biol. Sci. 2014, 4, 825–828. [Google Scholar]
- Heiser, P.; Sommer, O.; Schmidt, A.J.; Clement, H.W.; Hoinkes, A.; Hopt, U.T.; Schulz, E.; Krieg, J.C.; Dobschütz, E. Effects of antipsychotics and vitamin C on the formation of reactive oxygen species. J. Psychopharmacol. 2010, 24, 1499–1504. [Google Scholar] [CrossRef]
- Travica, N.; Ried, K.; Sali, A.; Scholey, A.; Hudson, I.; Pipingas, A. Vitamin C status and cognitive function: A systematic review. Nutrients 2017, 9, 960. [Google Scholar] [CrossRef]
- Dakhale, G.N.; Khanzode, S.D.; Khanzode, S.S.; Saoji, A. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology 2005, 182, 494–498. [Google Scholar] [CrossRef] [PubMed]
- U.S. Department of Agriculture, Agricultural Research Service. Available online: https://fdc.nal.usda.gov/ (accessed on 24 April 2020).
- Madireddy, S.; Madireddy, S. The role of diet in maintaining strong brain health by taking the advantage of the gut–brain axis. J. Food Nutr. Res. 2019, 7, 41–50. [Google Scholar] [CrossRef]
- Cieslak, K.; Feingold, J.; Antonius, D. Low Vitamin D levels predict clinical features of schizophrenia. Schizophr. Res. 2014, 159, 543–545. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Krivoy, A.; Onn, R.; Vilner, Y.; Hochman, E.; Weizman, S.; Paz, A.; Hess, S.; Sagy, R.; Kimhi-Nesher, S.; Kalter, E.; et al. Vitamin D supplementation in chronic schizophrenia patients treated with clozapine: A randomized, double-blind, placebo-controlled clinical trial. EBioMedicine 2017, 26, 138–145. [Google Scholar] [CrossRef] [Green Version]
- Lally, J.; Gaughran, F. Vitamin D in schizophrenia and depression: A clinical review. BJPsych Adv. 2019, 25, 240–248. [Google Scholar] [CrossRef] [Green Version]
- Samoes, B.; Silveira, C. The role of vitamin D in the pathophysiology of schizophrenia. Neuropsychiatry 2017, 7, 362–369. [Google Scholar] [CrossRef]
- Sheikhmoonesi, F.; Zarghami, M.; Mamashli, S.; Charati, J.Y.; Hamzehpour, R.; Fattahi, S.; Azadbakht, R.; Kashi, Z.; Ala, S.; Moshayedi, M.; et al. Effectiveness of vitamin D supplement therapy in chronic stable schizophrenic male patients: A randomized controlled trial. Iran. J. Pharm. Res. 2016, 15, 941–950. [Google Scholar]
- Zhu, J.L.; Luo, W.W.; Cheng, X.; Li, Y.; Zhang, Q.Z.; Peng, W.X. Vitamin D deficiency and schizophrenia in adults: A systematic review and meta–analysis of observational studies. Psychiatry Res. 2020, 288, 112959. [Google Scholar] [CrossRef]
- Soliman, R.H.; Oraby, M.I.; Hussein, M.; El-Shafy, S.A.; Mostafa, S. Could vitamin D deficiency have an impact on motor and cognitive function in Parkinson’s disease? Egypt. J. Neurol. Psychiatry Neurosurg. 2019, 55, 34. [Google Scholar] [CrossRef]
- Wrzosek, M.; Łukaszkiewicz, J.; Wrzosek, M.; Jakubczyk, A.; Matsumoto, H.; Piątkiewicz, P.; Radziwoń-Zaleska, M.; Wojnar, M.; Nowicka, G. Vitamin D and the central nervous system. Pharmacol. Rep. 2013, 65, 271–278. [Google Scholar] [CrossRef]
- Zhou, Z.; Zhou, R.; Zhang, Z.; Li, K. The association between vitamin D status, vitamin D supplementation, sunlight exposure, and Parkinson’s disease: A systematic review and meta–analysis. Med. Sci. Monit. 2019, 25, 666–674. [Google Scholar] [CrossRef] [PubMed]
- Chiang, M.; Natarajan, R.; Fan, X. Vitamin D in schizophrenia: A clinical review. Evid. Based Ment. Health 2016, 19, 6–9. [Google Scholar] [CrossRef] [PubMed]
- Graham, K.A.; Keefe, R.S.; Lieberman, J.A.; Calikoglu, A.S.; Lansing, K.M.; Perkins, D.O. Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia. Early Interv. Psychiatry 2015, 9, 397–405. [Google Scholar] [CrossRef] [PubMed]
- Ghaderi, A.; Banafshe, H.R.; Mirhosseini, N.; Moradi, M.; Karimi, M.; Mehrzad, F.; Bahmani, F.; Asemi, Z. Clinical and metabolic response to vitamin D plus probiotic in schizophrenia patients. BMC Psychiatry 2019, 19, 77. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ovesen, L.; Brot, C.; Jakobsen, J. Food contents and biological activity of 25-hydroxyvitamin D: A vitamin D metabolite to be reckoned with? Ann. Nutr. Metab. 2003, 47, 107–113. [Google Scholar] [CrossRef]
- Calvo, M.S.; Whiting, S.J.; Barton, C.N. Vitamin D fortification in the United States and Canada: Current status and data needs. Am. J. Clin. Nutr. 2004, 80, 1710S–1716S. [Google Scholar] [CrossRef] [Green Version]
- Balanza-Martinez, V. Nutritional supplements in psychotic disorders. Actas Esp. Psiquiatr. 2017, 45, 16–25. [Google Scholar]
- Wang, D.; Zhai, J.X.; Liu, D.W. Serum folate levels in schizophrenia: A meta-analysis. Psychiatry Res. 2016, 235, 83–89. [Google Scholar] [CrossRef]
- van de Lagemaat, E.E.; de Groot, L.C.P.G.M.; van den Heuvel, E.G.H.M. Vitamin B12 in relation to oxidative stress: A systematic review. Nutrients 2019, 11, 482. [Google Scholar] [CrossRef] [Green Version]
- Mitchell, E.S.; Conus, N.; Kaput, J. B vitamin polymorphisms and behavior: Evidence of associations with neurodevelopment, depression, schizophrenia, bipolar disorder and cognitive decline. Neurosci. Biobehav. Rev. 2014, 47, 307–320. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Y.; Hodgson, N.W.; Trivedi, M.S.; Abdolmaleky, H.M.; Fournier, M.; Cuenod, M.; Do, K.Q.; Deth, R.C. Decreased Brain Levels of Vitamin B12 in Aging, Autism and Schizophrenia. PLoS ONE 2016, 11, e0146797. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brown, H.E.; Roffman, J.L. Vitamin Supplementation in the Treatment of Schizophrenia. CNS Drugs 2014, 28, 611–622. [Google Scholar] [CrossRef] [PubMed]
- Tucker, K.L.; Rich, S.; Rosenberg, I.; Jacques, P.; Dallal, G.; Wilson, W.F.; Selhub, J. Plasma vitamin B12 concentrations relate to intake source in the Framingham offspring study. Am. J. Clin. Nutr. 2000, 71, 514–522. [Google Scholar] [CrossRef] [PubMed]
- Watanabe, F.; Bito, T. Vitamin B12 sources and microbial interaction. Exp. Biol. Med. 2018, 243, 148–158. [Google Scholar] [CrossRef] [PubMed]
- Fedosov, S.N.; Nexo, E.; Heegaard, C.W. Vitamin B12 and its binding proteins in milk from cow and buffalo in relation to bioavailability of B12. J. Dairy Sci. 2019, 102, 4891–4905. [Google Scholar] [CrossRef]
- Munusamy, U.; Abdullah, S.N.A. Vitamin E: Phytochemistry and molecular aspects. Plant. Hum. Health 2019, 2, 345–360. [Google Scholar] [CrossRef]
- de Lau, L.M.L.; Bornebroek, M.; Witteman, J.C.M.; Hofman, A.; Koudstaal, P.J.; Breteler, M.M.B. Dietary fatty acids and the risk of Parkinson disease: The rotterdam study. Neurology 2005, 64, 2040–2045. [Google Scholar] [CrossRef]
- Balanzá-Martínez, V.; Fries, G.R.; Colpo, G.D.; Silveira, P.P.; Portella, A.K.; Tabarés-Seisdedos, R.; Kapczinski, F. The therapeutic use of omega-3 fatty acids in bipolar disorder. Exp. Rev. Neurother. 2011, 11, 1029–1047. [Google Scholar] [CrossRef]
- Satogami, K.; Takahashi, S.; Yamada, S.; Ukai, S.; Shinosaki, K. Omega-3 fatty acids related to cognitive impairment in patients with schizophrenia. Schizophr. Res. Cogn. 2017, 9, 8–12. [Google Scholar] [CrossRef]
- Hsu, M.-C.; Huang, Y.-S.; Ouyang, W.-C. Beneficial effects of omega-3 fatty acid supplementation in schizophrenia: Possible mechanisms. Lipids Health Dis. 2020, 19, 159. [Google Scholar] [CrossRef]
- Crump, C.; Winkleby, M.A.; Sundquist, K.; Sundquist, J. Comorbidities and mortality in persons with schizophrenia: A Swedish national cohort study. Am. J. Psychiatry 2013, 170, 324–333. [Google Scholar] [CrossRef] [PubMed]
- Tessier, C.; Sweers, K.; Frajerman, A.; Bergaoui, H.; Ferreri, F.; Delva, C.; Lapidus, N.; Lamaziere, A.; Roiser, J.P.; De Hert, M.; et al. Membrane lipidomics in schizophrenia patients: A correlational study with clinical and cognitive manifestations. Transl. Psychiatry 2016, 6, e906. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pawełczyk, T.; Grancow, M.; Kotlicka-Antczak, M.; Trafalska, E.; Gębski, P.; Szemraj, J.; Żurner, N.; Pawełczyk, A. Omega-3 fatty acids in first–episode schizophrenia—A randomized controlled study of efficacy and relapse prevention (OFFER): Rationale, design, and methods. BMC Psychiatry 2015, 15, 97. [Google Scholar] [CrossRef] [Green Version]
- Berger, G.E.; Proffitt, T.; McConchie, M.; Yuen, H.; Wood, S.J.; Amminger, G.P.; Brewer, W.; McGorry, P.D. Ethyl-eicosapentaenoic acid in first-episode psychosis: A randomized, placebo-controlled trial. J. Clin. Psychiatry 2007, 68, 1867–1875. [Google Scholar] [CrossRef]
- Agostoni, C.; Nobile, M.; Ciappolino, V.; Delvecchio, G.; Tesei, A.; Turolo, S.; Crippa, A.; Mazzocchi, A.; Altamura, C.A.; Brambilla, P. The role of omega-3 fatty acids in developmental psychopathology: A systematic review on early psychosis, autism, and ADHD. Int. J. Mol. Sci. 2017, 18, 2608. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bozzatello, P.; Brignolo, E.; De Grandi, E.; Bellino, S. Supplementation with omega-3 fatty acids in psychiatric disorders: A review of literature data. J. Clin. Med. 2016, 5, 67. [Google Scholar] [CrossRef] [PubMed]
- Mahadik, S.P.; Pillai, A.; Joshi, S.; Foster, A. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int. Rev. Psychiatry 2006, 18, 119–131. [Google Scholar] [CrossRef] [PubMed]
- Sivrioglu, E.Y.; Kirli, S.; Sipahioglu, D.; Gursoy, B.; Sarandöl, E. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: An open–label pilot study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31, 1493–1499. [Google Scholar] [CrossRef]
- Torrey, E.F.; Davis, J.M. Adjunct treatments for schizophrenia and bipolar disorder: What to try when you are out of ideas. Clin. Schizophr. Relat. Psychoses 2012, 5, 208–216. [Google Scholar] [CrossRef]
- Palaniswamy, K.S.; Vishwanadha, V.P.; Singaravelu, S.R. Fish oil rich in eicosapentaenoic acid protects against oxidative stress-related renal dysfunction induced by TCDD in Wistar rats. Cell Stress Chaperones 2014, 19, 409–419. [Google Scholar] [CrossRef] [Green Version]
- Meital, L.T.; Windsor, M.T.; Perissiou, M.; Schulze, K.; Magee, R.; Kuballa, A.; Golledge, J.; Bailey, T.G.; Askew, C.D.; Russell, F.D. Omega-3 fatty acids decrease oxidative stress and inflammation in macrophages from patients with small abdominal aortic aneurysm. Sci. Rep. 2019, 9, 12978. [Google Scholar] [CrossRef] [PubMed]
- Abd El-Samee, L.D.; El-Wardany, I.; Abdel-Fattah, S.A.; Abd El-Azeem, N.A.; Elsharkawy, M.S. Dietary omega-3 and antioxidants improve long-chain omega-3 and lipid oxidation of broiler meat. Bull. Natl. Res. Cent. 2019, 43, 45. [Google Scholar] [CrossRef] [Green Version]
- Pawełczyk, T.; Grancow-Grabka, M.; Trafalska, E.; Szemraj, J.; Pawełczyk, A. Oxidative stress reduction related to the efficacy of n–3 polyunsaturated fatty acids in first episode schizophrenia: Secondary outcome analysis of the OFFER randomized trial. Prostaglandins Leukot. Essent. Fatty Acids 2017, 121, 7–13. [Google Scholar] [CrossRef] [PubMed]
- Sanguansri, L.; Augustin, M.A.; Lockett, T.J.; Abeywardena, M.Y.; Royle, P.J.; Mano, M.T.; Patten, G.S. Bioequivalence of n-3 fatty acids from microencapsulated fish oil formulations in human subjects. Br. J. Nutr. 2015, 113, 822–831. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vannice, G.; Rasmussen, H. Position of the academy of nutrition and dietetics: Dietary fatty acids for healthy adults. J. Acad. Nutr. Diet. 2014, 114, 136–153. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Simopoulos, A.P. Evolutionary aspects of diet: The omega-6/omega-3 ratio and the brain. Mol. Neurobiol. 2011, 44, 203–215. [Google Scholar] [CrossRef] [PubMed]
- Hsu, W.; Lane, H.; Lin, C. Brexpiprazole for the treatment of schizophrenia. Expert Opin. Pharmacother. 2017, 18, 217–223. [Google Scholar] [CrossRef]
- Bruijnzeel, D.; Yazdanpanah, M.; Suryadevara, U.; Tandon, R. Lurasidone in the treatment of schizophrenia: A critical evaluation. Expert Opin. Pharmacother. 2015, 16, 1559–1565. [Google Scholar] [CrossRef]
- Biagi, E.; Capuzzi, E.; Colmegna, F.; Mascarini, A.; Brambilla, G.; Ornaghi, A.; Santambrogio, J.; Clerici, M. Long-acting injectable antipsychotics in schizophrenia: Literature review and practical rerspective, with a focus on aripiprazole once-monthly. Adv. Ther. 2017, 34, 1036–1048. [Google Scholar] [CrossRef] [Green Version]
- Zhang, X.Y.; Tan, Y.L.; Cao, L.Y.; Wu, G.Y.; Xu, Q.; Shen, Y.; Zhou, D.F. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr. Res. 2006, 81, 291–300. [Google Scholar] [CrossRef]
- Correll, C.U.; Kohegyi, E.; Zhao, C.; Baker, R.A.; McQuade, R.; Salzman, P.M.; Sanchez, R.; Nyilas, M.; Carson, W. Oral aripiprazole as maintenance treatment in adolescent schizophrenia: Results from a 52-week, randomized, placebo-controlled withdrawal study. J. Am. Acad. Child Adolesc. Psychiatry 2017, 56, 784–792. [Google Scholar] [CrossRef] [PubMed]
- Croxtall, J.D. Aripiprazole: A review of its use in the management of schizophrenia in adults. CNS Drugs 2012, 26, 155–183. [Google Scholar] [CrossRef] [PubMed]
- Rapinesi, C.; Kotzalidis, G.D.; Mazzarini, L.; Brugnoli, R.; Ferracuti, S.; De Filippis, S.; Cuomo, I.; Giordano, G.; Del Casale, A.; Angeletti, G.; et al. Long-acting injectable (LAI) aripiprazole formulations in the Treatment of schizophrenia and bipolar disorder: A systematic review. Clin. Drug Investig. 2019, 39, 713–735. [Google Scholar] [CrossRef]
- de Bartolomeis, A.; Latte, G.; Tomasetti, C.; Iasevoli, F. Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: Relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches. Mol. Neurobiol. 2014, 49, 484–511. [Google Scholar] [CrossRef] [PubMed]
- Tuplin, E.W.; Holahan, M.R. Aripiprazole, a drug that displays partial agonism and functional selectivity. Curr. Neuropharmacol. 2017, 15, 1192–1207. [Google Scholar] [CrossRef] [Green Version]
- Kane, J.M.; Zhao, C.; Johnson, B.R.; Baker, R.A.; Eramo, A.; McQuade, R.D.; Duca, A.R.; Sanchez, R.; Peters-Strickland, T. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: Final efficacy analysis. J. Med. Econ. 2015, 18, 145–154. [Google Scholar] [CrossRef] [Green Version]
- Naber, D.; Hansen, K.; Forray, C.; Baker, R.A.; Sapin, C.; Beillat, M.; Peters-Strickland, T.; Nylander, A.; Hertel, P.; Andersen, H.S.; et al. Qualify: A randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr. Res. 2015, 168, 498–504. [Google Scholar] [CrossRef] [Green Version]
- Ribeiro, E.L.A.R.; de Mendonça Lima, T.; Vieira, M.E.B.; Storpirtis, S.; Aguiar, P.M. Efficacy and safety of aripiprazole for the treatment of schizophrenia: An overview of systematic reviews. Eur. J. Clin. Pharmacol. 2018, 74, 1215–1233. [Google Scholar] [CrossRef]
- Nasrallah, H.A.; Aquila, R.; Du, Y.; Stanford, A.D.; Claxton, A.; Weiden, P.J. Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia. CNS Spectr. 2019, 24, 395–403. [Google Scholar] [CrossRef] [Green Version]
- Diefenderfer, L.A.; Iuppa, C. Brexpiprazole: A review of a new treatment option for schizophrenia and major depressive disorder. Ment. Health Clin. 2018, 7, 207–212. [Google Scholar] [CrossRef]
- Frampton, J.E. Brexpiprazole: A review in schizophrenia. Drugs 2019, 79, 189–200. [Google Scholar] [CrossRef] [PubMed]
- Ward, K.; Citrome, L. Brexpiprazole for the maintenance treatment of adults with schizophrenia: An evidence-based review and place in therapy. Neuropsychiatr. Dis. Treat. 2019, 15, 247–257. [Google Scholar] [CrossRef] [Green Version]
- Correll, C.U.; Skuban, A.; Hobart, M.; Ouyang, J.; Weiller, E.; Weiss, C.; Kane, J.M. Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies. Schizophr. Res. 2017, 190, 191–194. [Google Scholar] [CrossRef] [PubMed]
- Das, S.; Barnwal, P.; Winston, B.A.; Mondal, S.; Saha, I. Brexpiprazole: So far so good. Ther. Adv. Psychopharmacol. 2016, 6, 39–54. [Google Scholar] [CrossRef] [Green Version]
- McEvoy, J.; Citrome, L. Brexpiprazole for the treatment of schizophrenia: A Review of this novel serotonin-dopamine activity modulator. Clin. Schizophr. Relat. Psychoses 2016, 9, 177–186. [Google Scholar] [CrossRef] [PubMed]
- Scarff, J.R. Brexpiprazole: A new treatment option for schizophrenia. Innov. Clin. Neurosci. 2016, 13, 26–29. [Google Scholar] [PubMed]
- Garnock-Jones, K.P. Brexpiprazole: A review in schizophrenia. CNS Drugs 2016, 30, 335–342. [Google Scholar] [CrossRef]
- Markovic, M.; Gallipani, A.; Patel, K.H.; Maroney, M. Brexpiprazole. Ann. Pharmacother. 2017, 51, 315–322. [Google Scholar] [CrossRef]
- Yee, A. Brexpiprazole for the treatment of schizophrenia. Expert Rev. Neurother. 2016, 16, 109–122. [Google Scholar] [CrossRef]
- Marder, S.R.; Hakala, M.J.; Josiassen, M.K.; Zhang, P.; Ouyang, J.; Weiller, E.; Weiss, C.; Hobart, M. Brexpiprazole in patients with schizophrenia: Overview of short- and long-term phase 3 controlled studies. Acta Neuropsychiatr. 2017, 29, 278–290. [Google Scholar] [CrossRef]
- Bravo-Mehmedbasic, A. Risperidone in the treatment of schizophrenia. Med. Arh. 2011, 65, 345–347. [Google Scholar] [CrossRef] [PubMed]
- Feng, Z.; Zhang, Y.; You, X.; Zhang, W.; Ma, Y.; Long, Q.; Liu, Z.; Hao, W.; Zeng, Y.; Teng, Z. Effects of risperidone on blood levels of interleukin-6 in schizophrenia: A meta-analysis. Medicine 2020, 99, e19694. [Google Scholar] [CrossRef] [PubMed]
- Rattehalli, R.D.; Zhao, S.; Li, B.G.; Jayaram, M.B.; Xia, J.; Sampson, S. Risperidone versus placebo for schizophrenia. Cochrane Database Syst. Rev. 2016, 12, CD006918. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jiang, X.; Wu, F.; Zhang, J.; Shi, L.; Hu, J.; Zhu, H.; Xiao, B.; Lin, W.; Wen, Y.; Shang, D. Effects of risperidone and aripiprazole on serum levels of prolactin, testosterone and estradiol in female patients with schizophrenia. Drug Res. 2018, 68, 410–414. [Google Scholar] [CrossRef]
- Dietrich-Muszalska, A.; Kontek, B. Lipid peroxidation in patients with schizophrenia. Psychiatry Clin. Neurosci. 2010, 64, 469–475. [Google Scholar] [CrossRef]
- Javed, A.; Arthur, H.; Curtis, L.; Hansen, L.; Pappa, S. Practical guidance on the use of lurasidone for the treatment of adults with schizophrenia. Neurol. Ther. 2019, 8, 215–230. [Google Scholar] [CrossRef] [Green Version]
- Zheng, W.; Cai, D.; Yang, X.; Li, L.; Zhang, Q.; Ng, C.H.; Ungvari, G.S.; Li, X.; Ning, Y.; Xiang, Y. Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials. J. Psychiatr. Res. 2018, 103, 244–251. [Google Scholar] [CrossRef]
- Goldman, R.; Loebel, A.; Cucchiaro, J.; Deng, L.; Findling, R.L. Efficacy and safety of lurasidone in adolescents with schizophrenia: A 6-week, randomized placebo-controlled study. J. Child Adolesc. Psychopharmacol. 2017, 27, 516–525. [Google Scholar] [CrossRef] [Green Version]
- Higuchi, T.; Ishigooka, J.; Iyo, M.; Yeh, C.; Ebenezer, E.G.; Liang, K.Y.; Lee, J.K.; Lee, S.Y.; Lin, S.K.; Yoon, B.; et al. Lurasidone in the treatment of schizophrenia: Results of a double-blind, placebo-controlled trial in Asian patients. Asia Pac. Psychiatry 2019, 11, e12352. [Google Scholar] [CrossRef]
- Correll, C.U.; Cucchiaro, J.; Silva, R.; Hsu, J.; Pikalov, A.; Loebel, A. Long-term safety and effectiveness of lurasidone in schizophrenia: A 22-month, open-label extension study. CNS Spectr. 2016, 21, 393–402. [Google Scholar] [CrossRef] [Green Version]
- Lincoln, J.; Tripathi, A. Lurasidone for schizophrenia. Drug Ther. Bull. 2015, 53, 30–32. [Google Scholar]
- Khokhar, J.Y.; Henricks, A.M.; Kirk, E.; Green, A.I. Unique effects of clozapine: A pharmacological perspective. Adv. Pharmacol. 2018, 82, 137–162. [Google Scholar] [PubMed]
- Sahni, S.; Chavan, B.S.; Sidana, A.; Kalra, P.; Kaur, G. Comparative study of clozapine versus risperidone in treatment-naive, first-episode schizophrenia: A pilot study. Indian J. Med. Res. 2016, 144, 697–703. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Siskind, D.J.; Lee, M.; Ravindran, A.; Zhang, Q.; Ma, E.; Motamarri, B.; Kisely, S. Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis. Aust. N. Z. J. Psychiatry 2018, 52, 751–767. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fakra, E.; Azorin, J. Clozapine for the treatment of schizophrenia. Expert Opin. Pharmacother. 2012, 13, 1923–1935. [Google Scholar] [CrossRef] [PubMed]
- Suzuki, T.; Uchida, H.; Watanabe, K.; Kashima, H. Factors associated with response to clozapine in schizophrenia: A review. Psychopharmacol. Bull. 2011, 44, 32–60. [Google Scholar]
- Vermeulen, J.M.; van Rooijen, G.; van de Kerkhof, M.P.J.; Sutterland, A.L.; Correll, C.U.; de Haan, L. Clozapine and long-term mortality risk in patients with schizophrenia: A systematic review and meta-analysis of studies lasting 1.1–12.5 years. Schizophr. Bull. 2019, 45, 315–329. [Google Scholar] [CrossRef]
- Lee, M.A.; Thompson, P.A.; Meltzer, H.Y. Effects of clozapine on cognitive function in schizophrenia. J. Clin. Psychiatry 1994, 55 (Suppl. B), 82–87. [Google Scholar]
- Andrade, C. Antipsychotic drugs in schizophrenia: Relative effects in patients with and without treatment resistance. J. Clin. Psychiatry 2016, 77, e1656–e1660. [Google Scholar] [CrossRef] [Green Version]
- Dietrich-Muszalska, A.; Kopka, J.; Kwiatkowska, A. The effects of ziprasidone, clozapine and haloperidol on lipid peroxidation in human plasma (in vitro): Comparison. Neurochem. Res. 2013, 38, 1490–1495. [Google Scholar] [CrossRef]
- Hendouei, N.; Farnia, S.; Mohseni, F.; Salehi, A.; Bagheri, M.; Shadfar, F.; Barzegar, F.; Hoseini, S.D.; Charati, J.Y.; Shaki, F. Alterations in oxidative stress markers and its correlation with clinical findings in schizophrenic patients consuming perphenazine, clozapine and risperidone. Biomed. Pharmacother. 2018, 103, 965–972. [Google Scholar] [CrossRef] [PubMed]
- Siskind, D.; McCartney, L.; Goldschlager, R.; Kisely, S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: Systematic review and meta-analysis. Br. J. Psychiatry 2016, 209, 385–392. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Adams, C.E.; Awad, G.A.; Rathbone, J.; Thornley, B.; Soares-Weiser, K. Chlorpromazine versus placebo for schizophrenia. Cochrane Database Syst. Rev. 2014, CD000284. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Adams, C.E.; Rathbone, J.; Thornley, B.; Clarke, M.; Borrill, J.; Wahlbeck, K.; Awad, G.A. Chlorpromazine for schizophrenia: A Cochrane systematic review of 50 years of randomised controlled trials. BMC Med. 2005, 3, 15. [Google Scholar] [CrossRef] [Green Version]
- Dudley, K.; Liu, X.; De Haan, S. Chlorpromazine dose for people with schizophrenia. Cochrane Database Syst. Rev. 2017, 4, CD007778. [Google Scholar] [CrossRef]
- Saha, K.B.; Bo, L.; Zhao, S.; Xia, J.; Sampson, S.; Zaman, R.U. Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. Cochrane Database Syst. Rev. 2016, CD010631. [Google Scholar] [CrossRef]
- Ficarra, S.; Russo, A.; Barreca, D.; Giunta, E.; Galtieri, A.; Tellone, E. Short-term effects of chlorpromazine on oxidative stress in erythrocyte functionality: Activation of metabolism and membrane perturbation. Oxid. Med. Cell. Longev. 2016, 2016, 2394130. [Google Scholar] [CrossRef] [Green Version]
- Muhieddine, D.; Moughnié, M.; Abdel-Razzak, Z. Short communication: Chlorpromazine causes a time-dependent decrease of lipids in Saccharomyces cerevisiae. Interdiscip. Toxicol. 2019, 12, 41–44. [Google Scholar] [CrossRef] [Green Version]
- Gangadhar, N.; Varambally, S. Yoga therapy for schizophrenia. Int. J. Yoga 2012, 5, 85–91. [Google Scholar]
- Ganguly, P.; Soliman, A.; Moustafa1, A.A. Holistic management of schizophrenia symptoms using pharmacological and non-pharmacological treatment. Front. Public Health 2018, 6, 166. [Google Scholar] [CrossRef]
- Health Quality Ontario. Cognitive behavioral therapy for psychosis: A health technology assessment. Ont. Health Technol. Assess. Ser. 2018, 18, 1–141. [Google Scholar]
- Jones, C.; Hacker, D.; Meaden, A.; Cormac, I.; Irving, C.B.; Xia, J.; Zhao, S.; Shi, C.; Chen, J. Cognitive behavioural therapy plus standard care versus standard care plus other psychosocial treatments for people with schizophrenia. Cochrane Database Syst. Rev. 2018, CD008712. [Google Scholar] [CrossRef]
- Sensky, T.; Turkington, D.; Kingdon, D.; Scott, J.L.; Scott, J.; Siddle, R.O.; O’Carroll, M.; Barnes, T.R.E. A randomized controlled trial of cognitive–behavioural therapy for persistent symptoms in schizophrenia resistant to medication. Arch. Gen. Psychiatry 2000, 57, 165–172. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hogarty, G.E.; Greenwald, D.P.; Eack, S.M. Durability and mechanism of effects of Cognitive Enhancement Therapy. Psychiatr. Serv. 2006, 57, 1751–1757. [Google Scholar] [CrossRef] [Green Version]
- Eack, S.M.; Hogarty, G.E.; Greenwald, D.P.; Hogarty, S.S.; Keshavan, M.S. Effects of cognitive enhancement therapy on employment outcomes in early schizophrenia: Results from a two-year randomized trial. Res. Soc. Work Pract. 2011, 21, 32–42. [Google Scholar] [CrossRef] [Green Version]
- Costa, R.; Bastos, T.; Probst, M.; Seabra, A.; Abreu, S.; Vilhena, E.; Rosenbaum, S.; Ward, P.B.; Corredeira, R. Association of lifestyle-related factors and psychological factors on quality of life in people with schizophrenia. Psychiatry Res. 2018, 267, 382–393. [Google Scholar] [CrossRef]
- Firth, J.; Carney, R.; Stubbs, B.; Teasdale, S.; Vancampfort, D.; Ward, P.; Berk, M.; Sarris, J. Nutritional deficiencies and clinical correlates in first-episode psychosis: A systematic review and meta-analysis. Schizophr. Bull. 2017, 44, 1275–1292. [Google Scholar] [CrossRef]
- Funk, M.; Drew, N.; Knapp, M. Mental health, poverty and development. J. Public Ment. Health 2012, 11, 166–185. [Google Scholar] [CrossRef] [Green Version]
- Sarris, J.; Logan, A.C.; Akbaraly, T.N.; Amminger, G.P.; Balanzá-Martínez, V.; Freeman, M.P.; Hibbeln, J.; Matsuoka, Y.; Mischoulon, D.; Mizoue, T.; et al. Nutritional medicine as mainstream in psychiatry. Lancet Psychiatry 2015, 2, 271–274. [Google Scholar] [CrossRef]
- Adamowicz, K.; Kucharska-Mazur, J. Dietary behaviors and metabolic syndrome in schizophrenia patients. J. Clin. Med. 2020, 9, 537. [Google Scholar] [CrossRef] [Green Version]
- Simonelli-Muñoz, A.J.; Fortea, M.I.; Salorio, P.; Gallego-Gomez, J.I.; Sánchez-Bautista, S.; Balanza, S. Dietary habits of patients with schizophrenia: A self-reported questionnaire survey. Int. J. Ment. Health Nurs. 2012, 21, 220–228. [Google Scholar] [CrossRef]
- Heald, A.; Pendlebury, J.; Anderson, S.; Narayan, V.; Guy, M.; Gibson, M.; Haddad, P.; Livingston, M. Lifestyle factors and the metabolic syndrome in schizophrenia: A cross-sectional study. Ann. Gen. Psychiatry 2017, 16, 12. [Google Scholar] [CrossRef] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Madireddy, S.; Madireddy, S. Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia. Brain Sci. 2020, 10, 742. https://doi.org/10.3390/brainsci10100742
Madireddy S, Madireddy S. Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia. Brain Sciences. 2020; 10(10):742. https://doi.org/10.3390/brainsci10100742
Chicago/Turabian StyleMadireddy, Samskruthi, and Sahithi Madireddy. 2020. "Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia" Brain Sciences 10, no. 10: 742. https://doi.org/10.3390/brainsci10100742